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Editorial
Malaria  vaccines  getting  close  to  clinical  reality
An important enabling concept for malaria vaccine development
has been the knowledge that clinical and parasitological immunity
develops after a number of naturally acquired malaria infections
[1]. Almost half a century ago it was shown that naturally acquired
antibodies were able to control parasitemia in humans [2]. Semi-
nal attenuated sporozoite studies in animal and human models
strengthened the belief that a highly protective vaccine was achiev-
able [3]. Expectations were further boosted with the advent of
recombinant protein technology in the mid-1980s. Effective vac-
cines were expected just around the corner, with new candidates
announced at regular intervals. As the years went by, however, suc-
cess did not readily materialize, feeding skepticism as to whether
a malaria vaccine was a realistic goal. As an example, at least 6
sequential formulations of the immunodominant circumsporozoite
protein were tested against controlled human malaria infection and
were rejected due to poor efﬁcacy [4] before the ﬁrst encouraging
protection signal was reported [5].
However, recent years have seen landmark achievements. In
2015, for the ﬁrst time, a meeting of experts, commissioned by the
European Medicine Agency (EMA), concluded with a positive rec-
ommendation for the use of the malaria vaccine RTS,S (Mosquirix)
in very young children, after a period of more 30 years of clinical
development [6]. Although modest in protective efﬁcacy and with
options for improvement lined up for testing, RTS,S in its current
conﬁguration may  nevertheless become a welcome addition to the
toolbox of malaria control measures. Importantly, it will serve as a
benchmark for next generation malaria vaccines, helping to identify
those with sufﬁciently improved efﬁcacy to merit further testing
and development. Assuming that RTS,S proceeds to licensure for
use in endemic areas, post-licensure follow-up and pharmacovig-
ilance studies as well as precise and transparent communication
to the community about beneﬁts and limitations should be priori-
tized. Additional good news is that at least seven other recombinant
protein vaccine candidates, based on either traditional or novel
antigens, or on antigen combinations, are undergoing clinical test-
ing [7]. Finally, major progress is being made by whole parasite
vaccine approaches including manufacturing techniques, regimens
and routes of administration [8–10].
Looking back over the past three decades, overly optimistic
viewpoints found their origin in the gross underestimation of the
complexity of parasite biology and protective immunity as well
as the technological and clinical challenges involved. In hindsight,
we note the absence of vaccines against any human parasitic
infection to emulate, and the many adaptive mechanisms allow-
ing the malaria parasite to evade the human immune response.
Addressing these pressing issues for effective vaccine development
requires substantial and appropriate ﬁnancial investments. There
is no simple or cheap solution to such complex scientiﬁc and
technical challenges.
Accordingly, approaches to vaccine development have evolved
over the decades. Originally, the main efforts were targeted at Plas-
modium falciparum life-cycle stage-speciﬁc proteins with emphasis
on blood stages, in order to mimic  naturally acquired immunity
and reduce clinical disease. However, effective blood stage vaccines
did not emerge, and leading candidates achieved strain-speciﬁc
protection at best [11]. The more recent focus on malaria erad-
ication and transmission reduction has shifted the emphasis to
pre-erythrocytic- and sexual stage-protein vaccines [7,12].
The evolution in vaccine development has gradually clariﬁed
impediments to success and has led to signiﬁcant progress:
(1) Poor immunogenicity of individual vaccine candidate antigens.
The introduction of virally vectored platforms and prime
boost strategies has substantially increased desired immune
responses [13], while the options for particulate delivery of
recombinant proteins have strengthened this critical vaccine
platform [14]. An intriguing and innovative concept has been
the targeted substitution of amino acids to improve MHC  bind-
ing of conserved, biologically critical peptide epitopes [15].
(2) Genetic and/or antigenic diversity of the selected target proteins.
This has resulted in poor efﬁcacy in ﬁeld trials in particular
for blood stage antigens that are under heavy and constant
immune pressure. Multiple approaches are under investiga-
tion to cover genetic diversity of natural P. falciparum variants
and have made progress in the induction of strain-transcending
immune responses [16]
(3) Insufﬁcient breadth and coverage of the induced immune response
based on mostly single antigens. One way  forward is to mix and
match individual antigens, particularly cross-stage antigens
expressed in different parts of the life cycle . Alternatively, intact
attenuated live parasite approaches may  counter immune eva-
sion through polymorphism by presenting the immune system
with 100s of antigens [8].
With regard to subunit vaccines, major emphasis and effort
are now focused on a subset of a dozen or so candidate pro-
teins (http://www.who.int/immunization/research/development/
Rainbow tables) that are critical for progression in the life cycle
and therefore attractive as targets for immune effector functions.
It is, however, well appreciated that these proteins have not been
systematically selected. It is therefore of paramount importance
to supply the pipeline with more and even better candidates, and
to develop methods for prioritization. The recent development
of systems biology and immunomics approaches has facilitated
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a rational approach to antigen discovery and should accelerate
progress [17].
Recent studies have conﬁrmed the great potency of whole
parasites attenuated in various ways to induce sterile protec-
tion in animals and in the controlled human malaria infection
model [8–10]. Clinical development of a cryopreserved radiation-
attenuated whole sporozoite vaccine has recently made a leap
forward by showing high level efﬁcacy after intravenous adminis-
tration [24]. The manufacture, cryopreservation and administration
of these vaccines require innovative approaches that are unconven-
tional in traditional vaccinology.
Vaccine testing primarily focuses on young children in sub-
Saharan Africa as the most susceptible risk group but there are other
special groups, including malaria-naïve travelers and military per-
sonnel [18] as well women of child-bearing age, where the risk of
severe diseases during pregnancy is great [19]. Speciﬁc approaches
and/or vaccine candidates are under investigation.
While P. falciparum is primarily responsible for the malaria bur-
den in sub-Saharan Africa, Plasmodium vivax is a major source of
morbidity in Asia and South America, equal to or surpassing P. fal-
ciparum in some areas. P. vivax is increasingly recognized for its
ability to induce severe disease, for the difﬁculty of reducing disease
burden in the community, and for the extreme challenge of elim-
ination. Although modest compared to P. falciparum in program
activities, there is progress toward clinical development of P. vivax
vaccines and this would beneﬁt from further prioritization [20].
Mathematical modeling of vaccine implementation under a
range of epidemiological scenarios provides support and guid-
ance for control and elimination strategies using a variety of
vaccine approaches and combinations [21]. The achievement of
these diverse objectives will be facilitated if funders can optimally
frame vaccine development policy and streamline the associated
pipelines [22].
The incidence of malaria has dropped by 40% over the past 15
years with an encouraging fall in morbidity and mortality. The
prevalence in children age 2-up-to-10 across endemic Africa has
halved since the year 2000 due to better implementation of existing
tools [23]. Notwithstanding this progress, the absolute ﬁgures are
still unacceptably high, and in many areas progress is stalled. The
inability to eliminate the parasite from its heartland using existing
measures is abundantly clear. The availability of a strongly efﬁca-
cious vaccine would enable further progress, and renew prospects
for eradication. Given the current momentum, we are optimistic:
the era of malaria vaccine deployment is now indeed realistically
just around the corner!
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